CRO Novella Clinical has appointed Dr. Karen Kelso as Director of Regulatory Affairs.
Kevin Johnson, Novella’s Global Head of Regulatory Affairs, said: “Karen’s regulatory experience in the U.S., Europe and Asia and her relationships with international agency officials will greatly benefit Novella’s medical device clients, many of whom are seeking to expand clinical trials to international markets.”
Kelso joins having previously served as Vice president of Regulatory Affairs and Clinical Studies at Vacutek in Scotland.
Dr. Daniel Carpenter has been promoted to Senior Vice President and General Manager at Comprehensive Clinical Development and will be responsible for all operations and business strategy implementation.
Elizabeth Harley, with over 14 years clinical research, experience has also been promoted to Vice President of Strategic Relationships.
President and COO of Comprehensive said: “We are evolving our team to keep us on the leading edge of the industry and these expanded roles will position us well for continued growth.”
Patheon has appointed Dr. Aqeel Fatmi to be the new Executive Vice President of Global Research & Development.
Prior to Patheon, Dr. Fatmi had served as Global Vice President of R&D at Banner Pharmacops.
"I am extremely pleased to be formally welcoming Aqeel to Patheon's executive team, as his expertise and leadership within the industry is truly remarkable" said James C. Mullen, Patheon's Chief Executive Officer. "In his new role, Aqeel will be focused on supporting the advancement of Patheon's recently acquired business unit focused solely on proprietary products and technology."
Synteract has appointed Dr. Philip Doren is the new Vice President of Biometrics.
Doren comes directly from Covance where he was Vice President, Clinical Data, Analysis and Reporting Organization.
The CRO Synteract has also hired Keith Kelson as Chief Financial Officer and member of its Executive Council.
Kelson, who brings over 12 years of financial experience to the role, is arriving from Insight Health Services Holdings Corporation where he served as Executive Vice President and Chief Financial Officer.
Synteract CEO Wendel Barr said: “The leadership acumen and industry expertise that both Phil and Keith bring to the table allows us to further enhance the quality and continuum of service that is critical to meeting the expectations of our clients' current and future needs, on an international scale."
Other appointments include:
Cytovance have appointed Maria Lopez as its Vice President of Quality. She has been in the biopharma industry for over 15 years and arrives at Cytovance having been Site Quality Head at Novartis.
She replaces Bill Minshall who has assumed a new role as Senior Vice President of Regulatory Affairs at the CMO.
United Allergy Services has announced a new member of its Board of Directors in Keith Johnson who has over 30 years of experience in healthcare diagnostics laboratories.
Steve Glaza has been appointed Director of Safety Assessment at SNBL USA, coming from over 30 years at Covance Laboratories.